

# Adiponectin: An Emerging Cardiovascular Risk Factor. The REFERENCE Study

Vivencio Barrios,<sup>a</sup> Ricardo Gómez-Huelgas,<sup>b</sup> Rosario Rodríguez,<sup>c</sup> and Pedro de Pablos-Velasco<sup>d</sup> on behalf of the REFERENCE study research group

<sup>a</sup>Departamento de Cardiología, Hospital Ramón y Cajal, Madrid, Spain

<sup>b</sup>Departamento de Medicina Interna, Hospital Carlos Haya, Malaga, Spain

<sup>c</sup>Sanofi-Aventis, Barcelona, Spain

<sup>d</sup>Departamento de Endocrinología, Universidad de Las Palmas, Las Palmas de Gran Canaria, Las Palmas, Spain

**Introduction and objectives.** Emerging cardiovascular (CV) risk factors such as adiponectin, glycosylated hemoglobin, waist circumference and the high-sensitivity C-reactive protein (hsCRP) level can aid CV risk stratification. It has been shown that classic factors alone are not sufficient to explain CV risk fully. The adiponectin level has been linked to insulin resistance, dyslipidemia, and coronary artery disease. This study investigated how the levels of adiponectin and other emerging risk factors are related to CV events in the Spanish population.

**Methods.** This cross-sectional study involved 999 patients. They were divided into cases, who had experienced a first CV event in the 3 months prior to the study, and controls. Anthropometric and laboratory parameters recorded both after the event and 3 years before the study started were obtained.

**Results.** Both a low adiponectin level and a high hsCRP level were associated with the occurrence of a CV event. In addition, obesity and a triglyceride level  $\geq 150$  mg/dL, both observed 3 years before the study, were also associated with the occurrence of an event. There was an inverse relationship between the plasma adiponectin level and waist circumference. Multivariate analysis identified the following significant variables: hsCRP level, a family history of early CV disease, and the high-density lipoprotein cholesterol (HDL-C) level 3 years earlier.

**Conclusions.** A low adiponectin level is associated with abdominal obesity. Emergent risk factors do not improve the predictive ability of the Systematic Coronary Risk Evaluation (SCORE) algorithm (which includes total cholesterol, HDL-C, blood pressure, and smoking). Further studies evaluating their contribution are needed.

**Key words:** *Adiponectin. C-reactive protein. Obesity. Vascular disease.*

## Adiponectina, un factor de riesgo cardiovascular emergente. Estudio REFERENCE

**Introducción y objetivos.** Los factores de riesgo emergentes como la adiponectina, la glucohemoglobina, el perímetro de cintura (PC) o la proteína C reactiva ultrasensible (PCRus) pueden ayudar a estratificar el riesgo cardiovascular (CV). Se ha observado que los factores clásicos por sí solos no pueden explicar por completo el riesgo. La adiponectina se ha relacionado con la resistencia a la insulina, la dislipemia y la enfermedad coronaria. Este estudio evaluó en la población española la relación entre la adiponectina y otros factores de riesgo emergentes con la aparición de un episodio CV.

**Métodos.** Se llevó a cabo un estudio transversal en 999 pacientes divididos en casos (los que habían padecido un primer episodio cardiovascular 3 meses antes del estudio) y controles. Se registraron datos antropométricos y analíticos después del episodio y 3 años antes del estudio.

**Resultados.** Las concentraciones bajas de adiponectina y elevadas de PCRus estaban asociadas con la presencia de un episodio CV. La obesidad y una concentración de triglicéridos  $\geq 150$  mg/dl 3 años antes del estudio también se asociaron con la aparición de un episodio. La adiponectina se asoció inversamente con el PC. Finalmente, en un análisis multivariable, los factores significativos fueron: la PCRus, la historia familiar de enfermedad CV precoz y el colesterol ligado a las lipoproteínas de alta densidad (HDL) 3 años antes.

**Conclusiones.** La adiponectina se relaciona con la obesidad abdominal. Los factores emergentes no mejoran la capacidad de predicción de los factores incluidos en las tablas de SCORE (colesterol total y de las HDL, PA y hábito tabáquico). Se precisarán otros estudios para evaluar mejor su contribución.

**Palabras clave:** *Adiponectina. Proteína C reactiva. Obesidad. Angiopatía.*

The researchers and hospitals participating in the REFERENCE study are listed in the Appendix.

Correspondence: Dr. V. Barrios Alonso.  
Departamento de Cardiología. Hospital Ramón y Cajal.  
Ctra. de Colmenar, km 9.100. 28034 Madrid. España.  
E-mail: vbarriosa@meditex.es; vbarrios.hrc@salud.madrid.org

Received February 27, 2008.

Accepted for publication June 25, 2008.

**ABBREVIATIONS**

BP: blood pressure  
 HbA<sub>1c</sub>: glycosylated hemoglobin  
 HDL-C: high density lipoprotein cholesterol  
 hsCRP: high-sensitivity C-reactive protein  
 LDL-C: low density lipoprotein cholesterol

**INTRODUCTION**

Cardiovascular disease is the main cause of premature death in most European populations.<sup>1</sup> Total cardiovascular risk estimation is the first step needed to establish primary prevention measures. Cardiovascular risk can be readily calculated in certain subgroups of patients and those with several risk factors.<sup>2</sup> Nevertheless, depending on the population studied, there are differences in the susceptibility to established risk factors and, therefore, in the accuracy of cardiovascular risk prediction.<sup>3-7</sup>

According to some authors, the classic cardiovascular risk factors such as smoking, hypertension, dyslipidemia, diabetes, obesity, sedentary lifestyle, and dietary factors do not completely explain the differences in the prevalence of cardiovascular disease between different populations.<sup>8-13</sup> Additional markers such as triglyceride and fasting glucose levels may be of great help in risk stratification and improving treatment directed toward specific populations. Therefore, these may be considered “emerging risk factors.”

Adiponectin is an adipocytokine secreted by adipocytes that regulates the body's energy metabolism by stimulating fatty acid oxidation, lowering plasma triglyceride levels, and improving glucose metabolism through an increase in insulin sensitivity.<sup>14</sup> In several studies,<sup>15,16</sup> hypoadiponectinemia has been observed in patients with obesity, diabetes mellitus, and coronary artery disease. In addition to its antidiabetogenic properties, adiponectin possesses an antiatherogenic effect and shows an inverse relationship with other risk factors, such as blood pressure (BP), total cholesterol, and low-density lipoprotein concentrations.<sup>17-20</sup> Cross-sectional population studies have shown that low concentrations of adiponectin are associated with an adverse risk profile.<sup>21,22</sup> Because of the existing differences related to geographic location, it is important to determine the relationship between adiponectin concentrations and cardiovascular risk factors specifically for the Spanish population. To date, only one cross-sectional study in this regard has been performed in Spain, in the Mediterranean population of Catalonia.

The authors reported a relationship between low adiponectin concentrations and insulin resistance.<sup>23</sup> Plasma adiponectin concentrations seem to show interpopulation variations, however, and this should be taken into account in larger studies.<sup>24</sup>

The aims of this study were to examine the correlation between plasma adiponectin concentrations and abdominal obesity in the Spanish population and investigate the relationship between certain emerging risk factors, such as abdominal obesity, and levels of adiponectin, triglycerides, glycosylated hemoglobin (HbA<sub>1c</sub>), high-sensitivity C-reactive protein (hsCRP), and fasting glucose, and the probability of experiencing a first cardiovascular event.

**METHODS****Procedures**

A cross-sectional, case-control study was undertaken in the population attended in the Spanish National Health Service, with the participation of 367 investigators from 170 centers. Subjects were recruited over approximately 4 months and enrolled consecutively; the investigator included the first 2 patients of cases and controls that fulfilled the selection criteria. Among 1160 patients included, 999 who came for outpatient consultation in the internal medicine, cardiology, or endocrinology departments were evaluated. The case group included 523 individuals who had a first cardiovascular event (ischemic heart disease, stroke, congestive heart disease, or peripheral artery disease) within the 3 months prior to inclusion in the study. The investigators classified the cardiovascular events by clinical evaluation. Angina was established on the clinical diagnosis and objective evidence of myocardial ischemia or coronary lesion. The control group included 476 individuals with no history of a cardiovascular event. Cardiovascular risk in cases and controls was estimated using the Systematic Coronary Risk Evaluation (SCORE) algorithm. Each case-control pair, recruited by the same investigator, was matched for sex, age ( $\pm 5$  years), and SCORE risk estimation ( $\pm 1\%$ ).

Patients were excluded if they had a cardiovascular event before the 3 months prior to the study visit, were in treatment with corticoids or oral retinoids, or were receiving antiobesity treatment. All patients gave informed written consent to participate. The study was approved by the Ethics Committee of Hospital Carlos Haya, in Malaga, Spain.

The study data were collected in 2 phases: a retrospective review and a current review of the medical records. During the study visit, personal and demographic data, cardiovascular history, medication, BP, body mass index (BMI), analytical parameters, cardiovascular risk factors, and risk estimation with the SCORE algorithm were recorded. The analytical parameters included total

cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), adiponectin, hsCRP, HbA<sub>1c</sub>, serum creatinine, and fasting glucose. The classic cardiovascular risk factors included smoking, a family history of premature cardiovascular disease, diabetes, sedentary lifestyle, and dyslipidemia.

Waist circumference was determined using a non-elastic metric tape measure placed between the border of the rib cage and the iliac crest. Abdominal obesity was classified according to the following definitions: >94 cm in men and >80 cm in women, according to the criteria of the International Diabetes Federation (IDF),<sup>25</sup> and >102 cm in men and >88 cm in women, according to the criteria of the National Cholesterol Education Program-Adult Treatment Panel (NCEP/ATP-III).<sup>26</sup> Hypertension was established when systolic BP was  $\geq 140$  mm Hg and/or diastolic BP  $\geq 90$  mm Hg (130 and 80 mm Hg respectively, in patients with diabetes) or the patient was currently taking antihypertensive treatment.

Patients were considered to have a sedentary lifestyle if they did not walk, run, or swim for 30 to 45 min 3 or 4 times per week. A family history of premature cardiovascular disease was determined in first-degree relatives aged <55 years for men and <65 years for women. A smoker was a person who smoked at least 10 cigarettes per day.<sup>27</sup> Hypercholesterolemia was established by a total cholesterol concentration of  $\geq 240$  mg/dL or current treatment with cholesterol-lowering drugs. Dyslipidemia was defined according to NCEP/ATP-III<sup>26</sup> recommendations for intermediate risk populations: total cholesterol concentration  $\geq 240$  mg/dL, LDL-C >130 mg/dL, HDL-C <40 mg/dL in men and <50 mg/dL in women, triglycerides  $\geq 150$  mg/dL, or current treatment with lipid-lowering drugs. Serum creatinine concentrations were considered to be mildly elevated at values of 1.3 to 1.5 mg/dL in men and 1.2 to 1.4 mg/dL in women. Patients were considered to have diabetes if their blood glucose levels were  $\geq 126$  mg/dL, they had received a diagnosis of diabetes, or they were taking oral diabetes medication or were under insulin treatment.

Adiponectin was measured at a core laboratory (Laboratorios Echevarne, Spain) using a human adiponectin kit (E09, Mediagnost Co. Ltd), with a sensitivity of <0.06 ng/mL and within-run and between-run coefficients of variation of 7%. The remaining analyses were performed according to the standard practice of each participating center.

## Statistical Methods

The 999 patients evaluated met all the inclusion criteria, and 80% of the study variables were available for them. Continuous variables are presented as the mean (SD). Comparisons between the groups of cases and controls were done with the Wilcoxon-Mann-Whitney test for

independent data. Categorical variables are represented by frequency counts and percentages of all the responses evaluated. Percentages were compared with the  $\chi^2$  test. We used 95% confidence intervals, and all *P* values were 2-tailed. A *P* value less than .05 was considered significant.

Univariate analysis with a nonconditional logistic regression model was used to assess the relationship between each risk factor and the probability of experiencing a cardiovascular event. A multivariate nonconditional logistic regression analysis was also performed. The relationship between adiponectin concentrations and abdominal obesity measurements were examined with linear regression analysis or Pearson/Spearman correlation coefficients. The data were processed with SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina, USA).

## RESULTS

### Baseline Characteristics

The anthropometric and metabolic characteristics of the study population are shown in Table 1. The comparisons were performed in 2 categories: immediately after the event and 3 years before the study in both the case and control groups.

In the cardiovascular risk estimation with the SCORE algorithm, 64.5% of patients in the case group and 71.2% in the control group were classified with a low risk score (<3%) or intermediate risk score (3%-4%). There were no significant differences in cardiovascular risk between cases and controls (*P*=.09) (Figure 1).

As to the obesity measurements, there were no differences in the BMI between cases and controls at either 3 years before the study or following the event; however, abdominal obesity (according to the IDF criteria) was greater in the case group than in the controls 3 years before the study (*P*=.012). There were no differences in the percentage of patients with central obesity in the assessment following the event.

The lipid profile also showed differences between cases and controls. In the analysis following the event, the cases had lower concentrations of total cholesterol, LDL-C, and HDL-C than the controls (*P*<.0001, *P*<.001, and *P*<.001, respectively); moreover, the cases presented lower plasma adiponectin concentrations (*P*=.0014) and higher hsCRP concentrations (*P*<.0001). Three years before the study, the cases showed significantly lower HDL-C (*P*<.0001) and higher triglycerides (*P*=.0296) than the controls. Adiponectin values from 3 years prior to the study were not available.

The cardiovascular events recorded are shown in Table 2. The most common cardiovascular condition was ischemic heart disease (70%), followed by cerebrovascular disease (20.5%), congestive heart failure (7.8%), and peripheral arterial disease (6.7%).

**TABLE 1. Anthropometric and Metabolic Characteristics Following the Event and 3 Years Before the Study**

Variables	After the Event			3 Years Before the Study		
	Cases	Controls	P	Cases	Controls	P
Age, y	61.7 (8.6)	60.79 (8.8)	.12			
Men, n (%)	368 (70.4)	324 (68.1)	.43			
BMI	29.5 (4.5)	29.5 (4.61)	.84	29.6 (4.9)	29.2 (4.8)	.25
Abdominal obesity, n (%)						
IDF criteria <sup>a</sup>	427 (81.8)	372 (78.1)	.15	299 (81.9)	183 (72.6)	.01 <sup>b</sup>
NCEP/ATP III criteria <sup>c</sup>	294 (56.3)	256 (53.8)	.42	143 (56.1)	125 (49.6)	.14
SBP, mm Hg	137.1 (18.6)	141.1 (4.3)	.04 <sup>b</sup>	142.97 (18.9)	142.07 (19.9)	.19
DBP, mm Hg	79.1 (9.6)	82.7 (9)	.001 <sup>b</sup>	84.5 (10.8)	84.4 (11.4)	.37
Fasting glucose, mg/dL	123.2 (41.6)	119.5 (41.6)	.05	121.3 (42.2)	120 (45.5)	.23
HbA <sub>1c</sub> , %	6.4 (1.3)	6.4 (1.4)	.46	7.03 (1.6)	6.8 (1.7)	.15
HbA <sub>1c</sub> ≥7%, n (%)	99 (31.4)	75 (28.5)	.34	101 (50.5)	76 (42.5)	.16
Total cholesterol, mg/dL	192 (47.2)	204.1 (39.4)	<.001 <sup>b</sup>	222.4 (45.6)	218.6 (40.6)	.23
LDL-C, mg/dL	118.1 (41.5)	124.23 (34.3)	.002 <sup>b</sup>	143 (40.4)	137.9 (35.2)	.14
HDL-C, mg/dL	45 (12.5)	50.65 (12.8)	<.001 <sup>b</sup>	46.6 (11.9)	49.8 (12.2)	<.001 <sup>b</sup>
Triglycerides, mg/dL	149.7 (72.3)	150.92 (80.9)	.52	167.8 (84)	158.9 (82.3)	.03 <sup>b</sup>
Triglycerides ≥150 mg/dL, n (%)	208 (40.2)	185 (39.2)	.81	262 (52.8)	210 (46.1)	.05 <sup>b</sup>
hsCRP, mg/dL	4.34 (4.6)	2.52 (3.1)	<.001 <sup>b</sup>	3.8 (4.2)	2.8 (3.4)	.14
hsCRP >1 mg/dL, n (%)	178 (72.4)	107 (51)	<.001 <sup>b</sup>	58 (65.9)	49 (57.6)	.18
Serum creatinine, mg/dL	1.19 (1.13)	1.31 (1.65)	.22	1.21 (1.37)	1.25 (1.55)	.08
Adiponectin, µg/mL	7.65 (5.9)	8.71 (6.1)	.001 <sup>b</sup>			
Adiponectin ≤4.5 µg/mL, n (%)	139 (33.3)	94 (25.1)	.01 <sup>b</sup>			

BMI indicates body mass index; DBP, diastolic blood pressure; HbA<sub>1c</sub>, glycosylated hemoglobin; HDL-C, high density lipoproteins; hsCRP, high-sensitivity C-reactive protein; LDL-C, low density lipoproteins; SBP, systolic blood pressure.

<sup>a</sup>>94 cm for men and >80 cm for women.


<sup>b</sup>Statistically significant.

<sup>c</sup>>102 cm for men and >88 cm for women.

χ<sup>2</sup> test or Wilcoxon test, depending on the type of data. Data are expressed as the mean (SD) except where specified.

The pharmacological treatments received following the event for cases and controls are shown in Table 3. In general, the case group had a significantly higher percentage of treated patients.

The relationship between emerging risk factors (abdominal obesity and concentrations of adiponectin, triglycerides, HbA<sub>1c</sub>, hsCRP, and fasting glucose) and the probability that a cardiovascular event would occur



**Figure 1.** Estimation of cardiovascular risk with the SCORE algorithm.

**TABLE 2. Type of Cardiovascular Event in the Past 3 Months**

Variable	Group of Cases, No. (%)
Patients evaluated	523 (100)
Ischemic heart disease	366 (70)
Acute myocardial infarction	160 (43.7)
Angina	123 (33.6)
Revascularization	115 (31.4)
Acute coronary syndrome	71 (19.4)
Not specified	24 (6.5)
Cerebrovascular disease	107 (20.5)
Stroke	62 (57.7)
Transient ischemic attack	39 (36.4)
Not specified	6 (5.6)
Congestive heart failure	41 (7.8)
Peripheral arterial disease	35 (6.7)

was investigated. There were no significant differences between the case-control pairs with regard to cardiovascular risk determined by the SCORE algorithm. The relationship between emerging risk factors and development of a cardiovascular event are shown in Figure 2.

Adiponectin values  $\leq 4.5$   $\mu\text{g/mL}$  following the episode significantly correlated with occurrence of a cardiovascular event, with an odds ratio (OR) of 1.5 (95% confidence interval [CI], 1.10-2.04;  $P=.011$ ); hsCRP  $> 1$   $\text{mg/dL}$  also showed a significant relationship (OR=2.52; 95% CI, 1.71-3.72;  $P<.0001$ ). In the analysis of the data obtained in the 3 years before the study, the factors related to the development of a cardiovascular episode were

abdominal obesity, according to the criteria of both the IDF (OR=1.70; 95% CI, 1.02-2.85;  $P=.0443$ ) and NCEP/ATP-III (OR=1.71; 95% CI, 1.10-2.67;  $P=.0443$ ) and triglycerides  $\geq 150$   $\text{mg/dL}$  (OR=.31; 95% CI, 1.02-1.70;  $P=.037$ ).

The classic risk factors associated with a cardiovascular event 3 years before the study were smoking (OR=1.38; 95% CI, 1.07-1.79;  $P=.013$ ) and HDL-C level (OR=1.25; 95% CI, 1.07-1.39;  $P=.0002$ ). The associated factors following the event were hypercholesterolemia (OR=1.50; 95% CI, 1.16-1.94;  $P=.002$ ), smoking more than 20 cigarettes per day (OR=1.75; 95% CI, 1.14-2.70;  $P=.010$ ), a family history of premature cardiovascular disease (OR=1.70; 95% CI, 1.23-2.38;  $P=.001$ ), and elevated serum creatinine values (OR=1.28; 95% CI, 0.84-1.97;  $P=.247$ ).

The emerging and classic risk factors that were significant in the univariate analysis were included in a multivariate analysis (Figure 3). The 3 factors that ultimately remained in the model were current hsCRP concentration, family history of premature cardiovascular disease, and HDL-C 3 years before the study. The model presented an accuracy rate of 68.2%. The adjusted OR for HDL-C 3 years before was 0.97 (95% CI, 0.95-0.99). Individuals with HDL-C levels 10 units lower 3 years ago presented a nearly 40% higher probability of experiencing a cardiovascular event than those with levels 10 units higher.

Plasma adiponectin concentrations presented an inverse relationship with waist circumference (Spearman rank correlation [ $\rho$ ] = -0.012 and  $P=.0118$ ). Lastly, an inverse correlation was also found between adiponectin and HDL-C concentration in the group of cases (Spearman  $\rho = -0.206$ ;  $P<.0001$ ).


**TABLE 3. Pharmacological Treatment Following the Event for Cases and Controls**

Variable	Cases	Controls	$P^a$
Patients evaluated	523 (100)	476 (100)	
Diuretics	177 (33.8)	150 (31.5)	.43
Beta-blockers	291 (55.6)	104 (21.8)	<.001 <sup>b</sup>
Calcium channel blockers	148 (28.3)	105 (22.1)	.02 <sup>b</sup>
ACE inhibitors	202 (38.6)	113 (23.7)	<.001 <sup>b</sup>
ARB	165 (31.5)	176 (37)	.07
Other antihypertensive agents	36 (6.9)	24 (5)	.22
Antiplatelet agents	444 (84.9)	164 (34.5)	<.001 <sup>b</sup>
Anticoagulants	42 (8)	29 (6.1)	.23
Statins	396 (75.7)	239 (50.2)	<.001 <sup>b</sup>
Fibrates	31 (5.9)	33 (6.9)	.52
Other lipid-lowering agents	29 (5.5)	28 (5.9)	.82
Insulin	82 (15.7)	60 (12.6)	.16
Oral hypoglycemic agents	128 (24.5)	113 (23.7)	.79

ACE inhibitors indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.

<sup>a</sup> $\chi^2$  test.

<sup>b</sup>Statistically significant.



**Figure 2.** Univariate analysis of emerging risk factors for a cardiovascular event. \*Statistically significant.



**Figure 3.** Multivariate analysis of emerging and classic cardiovascular risk factors. \*Odds ratio per each 1-unit increase.

## DISCUSSION

Current cardiovascular risk scales present limitations for predicting the probability of experiencing a cardiovascular event. In our series, only 35.5% of patients

who had an event showed high-risk status according to the SCORE algorithm. The role of emerging risk factors for improving the predictive power of current risk scales is controversial.<sup>28</sup> Because of their pandemic character

and their impact on the population, the emerging factors related with obesity are of particular interest. Adiponectin is a cytokine related with obesity. This is the first study that analyzes the relationship between adiponectin and cardiovascular disease in a broad sample of patients distributed over all of Spain.

In the population studied, an adiponectin concentration  $\leq 4.5$   $\mu\text{g/mL}$  was associated with a risk of experiencing a first cardiovascular event. These results are consistent with those of other authors<sup>22,29</sup> who have related hypoadiponectinemia with coronary disease. Although the cardiovascular event might have occurred up to 3 months before inclusion in this study, the adiponectin concentrations obtained after the event can be considered reliable. It has been shown that adiponectin values are a good predictor of secondary cardiovascular events over 7 years of follow-up.<sup>30</sup>

This study also showed that plasma adiponectin concentrations are inversely related to waist circumference and abdominal obesity. The results concur with those of other studies that show a relationship between plasma adiponectin concentrations and obesity, insulin resistance, and coronary disease.<sup>15,22,30,31</sup> Moreover, a correlation was found between adiponectin and lipoprotein levels, in particular HDL-C. Other authors have indicated that the risk of experiencing a cardiovascular event is substantially correlated to abdominal obesity measurements and lipid metabolism.<sup>29,32</sup> Our results support the idea that there is a relationship between adiponectin and lipid metabolism.

In addition to plasma adiponectin, a relationship was found between hsCRP concentrations following the event and the cardiovascular event (Figure 2). Although circulating hsCRP is a marker of inflammation, it is not clear whether it is a true predictor of a cardiovascular event, and there are controversial proposals in this regard.<sup>33,34</sup> Assessment of emerging factors measured at 3 years before the study showed a relationship between abdominal obesity and triglyceride concentrations, and development of a cardiovascular event. These risk factors lost significance following the episode, and low adiponectin concentrations and high hsCRP concentrations remained as the only significant emerging factors. Nonetheless, the multivariate analysis showed that hsCRP was the only emerging factor significantly associated with a cardiovascular event. Adiponectin may have lost a significant relationship because of the limitations of the study.

The data from the present study show an improvement in abdominal obesity and BP in the group of cases with respect to the controls, in the interval from 3 years before the start of the study to the measurements taken after the event. These differences may be due to the implementation of lifestyle changes and to the pharmacological treatment given after a cardiovascular event. Likewise, secondary prevention measures may have contributed to improvements in the lipid profile, which showed decreases in serum concentrations of total cholesterol, LDL-C and

triglycerides. It is interesting to note, however, that HDL-C concentrations measured after the event persisted at levels lower than the controls, which indicates that the drugs used, such as statins and other lipid-lowering agents, did not produce significant changes in HDL-C concentrations.

The present study has several limitations that should be specified. First, some of the measurements at 3 years before the study (waist circumference, HbA<sub>1c</sub>, and hsCRP) were not available for all the participants and this may have had an effect on the estimations of total risk. In addition, selection of patients who had a recent cardiovascular event and the size of the sample may have introduced bias in the study, with overestimation of risk. The fact that neurologists were not included may also have resulted in underestimation of the number of patients with cardiovascular disease and the relationship of this condition with adiponectin; nonetheless, internal medicine specialists attend a large part of these cases, and this is reflected in the percentage of stroke patients in our study population (20%).

Adiponectin was measured following the event and it cannot be concluded that this factor was unequivocally associated with the disease because it lost significance in the multivariate analysis and was not included in the secondary prevention measures.

## CONCLUSIONS

Emerging risk factors may provide a new opportunity to improve the currently available risk estimations. This study shows that adiponectin is related to central obesity and cardiovascular disease in the Spanish population. Notwithstanding, a cohort study is needed to determine whether this factor will improve the predictive capacity of the SCORE algorithm. Moreover, because of the high prevalence of obesity in the Spanish population, the risk factors related to this condition (such as adiponectin) may be more useful for improving risk prediction in our population. However, additional studies should be performed to better evaluate the contribution of the emerging risk factors. The task of adding new data that will help to estimate patient risk, perhaps even better than the classic risk factors, has considerable, positive clinical relevance.

## ACKNOWLEDGMENTS

The authors would like to express their thanks to the medical writing Department of Infociencia S.L.

## REFERENCES

1. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovás J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. *J Epidemiol Community Health.* 2003;57:634-8.

2. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2007;28:1462-536.
3. de Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*. 2003;24:1601-10.
4. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA*. 2001;286:180-7.
5. Marrugat J, Senti M. Why mortality from heart disease is low in France. High cholesterol may not have same effect on cardiovascular risk in southern Europe as elsewhere. *BMJ*. 2000;320:250.
6. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. *Eur Heart J*. 2003;24:1903-11.
7. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany —Results from the MONICA Augsburg and the PROCAM cohorts. *Eur Heart J*. 2003;24:937-45.
8. Masia R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. *J Epidemiol Community Health*. 1998;52:707-15.
9. Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. *Heart*. 2000;84:238-44.
10. Artaud-Wild SM, Connor SL, Sexton G, Connor WE. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. *Circulation*. 1993;88:2771-9.
11. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovás J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. *Rev Esp Cardiol*. 2003;56:253-61.
12. Mostaza JM, Vicente I, Taboada M, Laguna F, Echániz A, García-Iglesias F, et al. La aplicación de las tablas del SCORE a varones de edad avanzada triplica el número de sujetos clasificados de alto riesgo en comparación con la función de Framingham. *Med Clin (Barc)*. 2005;124:487-90.
13. Pyorala K. Assessment of coronary heart disease risk in populations with different levels of risk. *Eur Heart J*. 2000;21:348-50.
14. Palomer X, Pérez A, Blanco-Vaca F. Adiponectina: un nuevo nexo entre obesidad, resistencia a la insulina y enfermedad cardiovascular. *Med Clin (Barc)* 2005;124:388-95.
15. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun*. 1999;257:79-83.
16. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol*. 2000;20:1595-9.
17. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. *JAMA*. 2004;291:1730-7.
18. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. *Diabetes Care*. 2002;25:971-6.
19. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. *J Biol Chem*. 2002;277:25863-6.
20. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. *Circulation*. 2001;103:1057-63.
21. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. *Circ J*. 2004;68:975-81.
22. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypo adiponectinemia with coronary artery disease in men. *Arterioscler Thromb Vasc Biol*. 2003;23:85-9.
23. Salas-Salvado J, Granada M, Bullo M, Corominas A, Casas P, Foz M. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. *Metabolism*. 2007;56:1486-92.
24. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectin levels. *Metabolism*. 2004;53:1-3.
25. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome —A new worldwide definition. *Lancet*. 2005;366:1059-62.
26. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486-97.
27. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens*. 2003;21:1011-53.
28. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med*. 2006;355:2631-9.
29. Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. *Eur Heart J*. 2005;26:1640-6.
30. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. *Am J Cardiol*. 2007;100:569-74.
31. Kojima S, Funahashi T, Sakamoto T, Miyamoto S, Soejima H, Hokamaki J, et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. *Heart*. 2003;89:667.
32. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia*. 2003;46:459-69.
33. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. *Circulation*. 1998;97:425-8.
34. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med*. 2004;350:1387-97.

**APPENDIX 1. Investigators Participating in the REFERENCE Study**

---

F. Madruga, E. Velasco, R. Giménez, J.M. Rubio, J.A. López, J. Toril, A. Ordóñez, A. Yoldi, J.B. Montagud, J. Pinar, M.L. Fernández, R. Gómez, A. Sánchez, J.A. Martín, L. Mateos, J.A. Díaz, M.A. Suárez, J. Saban, R. Arroyo, J. López, C. Fontanals, A. López, R. Marín, A. Chacón, J.F. Carretero, C. Hernández, L. Pérez, M.R. Villar, J.R. Villar, J.J. Gorgojo, E. Barroso, P. Álvarez, M. Campillo, M. Camafort, G. Mazzanti, J. Garre, C. Morales, F.J. Conde, P. Gómez, F. Fernández, S. Suárez, M.T. Villarroel, F.M. Salgado, J. Egido, J. Enjuto, M.A. Gargallo, J.A. García, L.M. Azcona, J.L. Zamorano, I. Candel, V. Serra, A.M. García, D. de Luis, E. Romero, J.M. Guerra, F.J. Gómez, J. Fuertes, C. Daniel, S.J. Gunther, D. Bellido, J.C. Yañez, F. Soto, P. Rigueiro, J.M. García, J.L. Díaz, G. Sotres, J.J. Rondan, A. Aziz, V. Barriales, F. Asensio, J.M. Richard, S. García, A. Rodrigo, J. Pérez, P. Ruiz, J. Angel, R. Gascueña, R. Ortiz, M. Rayo, E. Martínez, O. González, A. Ortiz, L.F. Gómez, S. Donnay, D. Melehi, P. Horcajo, F. García, J. Gómez, A. Calderón, M.C. Fernández, R. Pujadas, J. Rafael, O. Alfani, G. Virgos, M. Elsaheb, J. Recio, S. Montull, X. Abaridia, N. Sucunza, R.M. Borralló, M.A. Palos, L.A. Fernández, J.M. Arribas, L. Quintas, I. Camacho, P.M. Montes, J.A. Novales, J.I. Catalán, R. Arteaga, J. Ezcurdia, C. Moreno, M. Morillas, H. García, M. Ribas, J. Ortiz, I. Segura, J. Soler, T. Ripoll, J. Fosch, R. Moreno, M. Domenech, M.T. Antonio, J. Viguera, C. Paytubi, P. Blanch, G. Cuatrecasas, J.M. Gómez, A. Laguna, J. Mayos, M.C. Lapuebla, A. Morales, C. Silva, S. Taberna, A. Cordero, S. Pérez, I. Madariaga, J.I. Elejalde, R. Ancin, G. Tiberio, M.L. Gracia, M.A. Berdun, A. García, R. Gayán, A. Sanz, P. Ferriz, M.M. Piedecausa, A. García, A. Toral, E. Hernández, A. Carnero, J. Arribas, A. Hernández, B. García, M. González, T. Martínez, J.D. Mediavilla, C. Fernández, J.A. Romero, A. González, R. Fajardo, E. Ramos, O. Aramburu, F.J. Rivera, J.L. Arias, J. Beltrán, I. Melguizo, P.C. Mateos, M.E. Mendoza, S.P. Romero, J. Motero, J.A. Guevara, H. Sánchez, J.M. García, A. Espino, J.M. Varela, J.A. Lobon, B. Jiménez, J.M. Arizón, J. Mora, I. Piñero, D. Gaitán, D. Fernández, J.R. Carmona, A.M. Garrido, S. Pérez, J.J. Gómez, A. Costo, O. Alfredo, G. Marcos, Y. Porras, J. Hernández, J. Morales, A. García, J.C. Pérez, M.M. Suárez, P. Jiménez, F.J. Martínez

---